首页 > 最新文献

Disease Markers最新文献

英文 中文
RETRACTION: The Increased PTK7 Expression Is a Malignant Factor in Cervical Cancer. 结论：PTK7表达增高是宫颈癌的恶性因子。
4区 医学 Q3 Medicine
Disease Markers
Pub Date : 2025-05-07 eCollection Date: 2025-01-01 DOI: 10.1155/dim/9817180
Disease Markers

[This retracts the article DOI: 10.1155/2019/5380197.].

[本文撤回文章DOI: 10.1155/2019/5380197.]。
{"title":"RETRACTION: The Increased PTK7 Expression Is a Malignant Factor in Cervical Cancer.","authors":"Disease Markers","doi":"10.1155/dim/9817180","DOIUrl":"https://doi.org/10.1155/dim/9817180","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.1155/2019/5380197.].</p>","PeriodicalId":11201,"journal":{"name":"Disease Markers","volume":"2025 ","pages":"9817180"},"PeriodicalIF":0.0,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12077965/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RETRACTION: Kinesin Family Member 18A (KIF18A) Contributes to the Proliferation, Migration, and Invasion of Lung Adenocarcinoma Cells In Vitro and In Vivo. 撤回：运动蛋白家族成员18A （KIF18A）在体外和体内参与肺腺癌细胞的增殖、迁移和侵袭。
4区 医学 Q3 Medicine
Disease Markers
Pub Date : 2025-05-07 eCollection Date: 2025-01-01 DOI: 10.1155/dim/9808595
Disease Markers

[This retracts the article DOI: 10.1155/2019/6383685.].

[本文撤回文章DOI: 10.1155/2019/6383685.]。
{"title":"RETRACTION: Kinesin Family Member 18A (KIF18A) Contributes to the Proliferation, Migration, and Invasion of Lung Adenocarcinoma Cells In Vitro and In Vivo.","authors":"Disease Markers","doi":"10.1155/dim/9808595","DOIUrl":"https://doi.org/10.1155/dim/9808595","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.1155/2019/6383685.].</p>","PeriodicalId":11201,"journal":{"name":"Disease Markers","volume":"2025 ","pages":"9808595"},"PeriodicalIF":0.0,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12077973/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RETRACTION: AK4 Promotes the Progression of HER2-Positive Breast Cancer by Facilitating Cell Proliferation and Invasion. 撤回：AK4通过促进细胞增殖和侵袭促进her2阳性乳腺癌的进展。
4区 医学 Q3 Medicine
Disease Markers
Pub Date : 2025-05-07 eCollection Date: 2025-01-01 DOI: 10.1155/dim/9862076
Disease Markers

[This retracts the article DOI: 10.1155/2019/8186091.].

[本文撤回文章DOI: 10.1155/2019/8186091]。
{"title":"RETRACTION: AK4 Promotes the Progression of HER2-Positive Breast Cancer by Facilitating Cell Proliferation and Invasion.","authors":"Disease Markers","doi":"10.1155/dim/9862076","DOIUrl":"https://doi.org/10.1155/dim/9862076","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.1155/2019/8186091.].</p>","PeriodicalId":11201,"journal":{"name":"Disease Markers","volume":"2025 ","pages":"9862076"},"PeriodicalIF":0.0,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12077969/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RETRACTION: MCOLN1 Promotes Proliferation and Predicts Poor Survival of Patients with Pancreatic Ductal Adenocarcinoma. 回撤：MCOLN1促进胰腺导管腺癌患者的增殖并预测其不良生存率。
4区 医学 Q3 Medicine
Disease Markers
Pub Date : 2025-05-06 eCollection Date: 2025-01-01 DOI: 10.1155/dim/9850902
Disease Markers

[This retracts the article DOI: 10.1155/2019/9436047.].

[本文撤回文章DOI: 10.1155/2019/9436047.]。
{"title":"RETRACTION: MCOLN1 Promotes Proliferation and Predicts Poor Survival of Patients with Pancreatic Ductal Adenocarcinoma.","authors":"Disease Markers","doi":"10.1155/dim/9850902","DOIUrl":"10.1155/dim/9850902","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.1155/2019/9436047.].</p>","PeriodicalId":11201,"journal":{"name":"Disease Markers","volume":"2025 ","pages":"9850902"},"PeriodicalIF":0.0,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12074834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RETRACTION: Nesfatin-1/Nucleobindin-2 Is a Potent Prognostic Marker and Enhances Cell Proliferation, Migration, and Invasion in Bladder Cancer. 结论：Nesfatin-1/ nucleobinin -2是膀胱癌的有效预后标志物，可促进细胞增殖、迁移和侵袭。
4区 医学 Q3 Medicine
Disease Markers
Pub Date : 2025-04-26 eCollection Date: 2025-01-01 DOI: 10.1155/dim/9803765
Disease Markers

[This retracts the article DOI: 10.1155/2018/4272064.].

[本文撤回文章DOI: 10.1155/2018/4272064]。
{"title":"RETRACTION: Nesfatin-1/Nucleobindin-2 Is a Potent Prognostic Marker and Enhances Cell Proliferation, Migration, and Invasion in Bladder Cancer.","authors":"Disease Markers","doi":"10.1155/dim/9803765","DOIUrl":"10.1155/dim/9803765","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.1155/2018/4272064.].</p>","PeriodicalId":11201,"journal":{"name":"Disease Markers","volume":"2025 ","pages":"9803765"},"PeriodicalIF":0.0,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12049245/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RETRACTION: HuR Promotes the Progression of Gastric Cancer through Mediating CDC5L Expression. 结论：HuR通过介导CDC5L的表达促进胃癌的进展。
4区 医学 Q3 Medicine
Disease Markers
Pub Date : 2025-03-31 eCollection Date: 2025-01-01 DOI: 10.1155/dim/9838093
Disease Markers

[This retracts the article DOI: 10.1155/2022/5141927.].

[此撤回文章DOI: 10.1155/2022/5141927.]。
{"title":"RETRACTION: HuR Promotes the Progression of Gastric Cancer through Mediating CDC5L Expression.","authors":"Disease Markers","doi":"10.1155/dim/9838093","DOIUrl":"https://doi.org/10.1155/dim/9838093","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.1155/2022/5141927.].</p>","PeriodicalId":11201,"journal":{"name":"Disease Markers","volume":"2025 ","pages":"9838093"},"PeriodicalIF":0.0,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11976036/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RETRACTION: Long Noncoding RNA AFAP1-AS1 Promotes Cell Proliferation and Metastasis via the miR-155-5p/FGF7 Axis and Predicts Poor Prognosis in Gastric Cancer. 回顾：长链非编码RNA AFAP1-AS1通过miR-155-5p/FGF7轴促进细胞增殖和转移，并预测胃癌预后不良。
4区 医学 Q3 Medicine
Disease Markers
Pub Date : 2025-02-22 eCollection Date: 2025-01-01 DOI: 10.1155/dim/9878012
Disease Markers

[This retracts the article DOI: 10.1155/2020/8140989.].

[本文撤回文章DOI: 10.1155/2020/8140989.]。
{"title":"RETRACTION: Long Noncoding RNA AFAP1-AS1 Promotes Cell Proliferation and Metastasis via the miR-155-5p/FGF7 Axis and Predicts Poor Prognosis in Gastric Cancer.","authors":"Disease Markers","doi":"10.1155/dim/9878012","DOIUrl":"10.1155/dim/9878012","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.1155/2020/8140989.].</p>","PeriodicalId":11201,"journal":{"name":"Disease Markers","volume":"2025 ","pages":"9878012"},"PeriodicalIF":0.0,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11873303/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of rs599839 Polymorphism on Coronary Artery Disease Risk in Saudi Diabetic Patients. 沙特糖尿病患者 rs599839 多态性对冠心病风险的影响
4区 医学 Q3 Medicine
Disease Markers
Pub Date : 2024-08-07 eCollection Date: 2024-01-01 DOI: 10.1155/2024/8278727
Neda M Bogari, Ahmad O Babalghith, Zohor Asaad Azher, Ahmad Hasan Mufti, Abdellatif Bouazzaoui, Hussain Banni, Abdulelah Awaji Madkhali, Ahmed Alahmadi, Reem M Allam

Background: Coronary artery diseases may be affected by several genetic and nongenetic factors. Single-nucleotide polymorphism (SNP) rs599839 and type 2 diabetes mellitus (T2DM) can affect the occurrence and severity of coronary artery disease (CAD).

Methods: Our aim was to investigate how T2DM and the rs599839 variant affected serum lipid levels and the degree of CAD patients' coronary artery stenosis. rs599839 polymorphism genotyping was done on Saudi patients with coronary angiography performed previously. Patients enrolled were divided into group A (360 DM patients), group B (225 DM patients with CAD), and group C (190 healthy volunteers as control).

Results: Individuals with diabetes and CAD who possessed the GG genotype in rs599839 exhibited markedly reduced means of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG; 224.5, 116.2, and 221.4 versus 251.6, 131.3, and 261.7 mg/dl, p=0.003, 0.007, and 0.025, respectively) than AA genotype. The odds ratio and the confidence interval of 95% for G allele carriers of rs599839 were OR = 0.62, 95% CI: 0.41-0.82, and p=0.003, among diabetic patients with CAD.

Conclusions: In patients with diabetic CAD, the locus 1p13.3 polymorphism rs599839 was found to be substantially correlated with serum lipid levels. Furthermore, among Saudi patients with diabetes, the G allele of rs599839 variant lowers the CAD risk.

背景：冠状动脉疾病可能受到多种遗传和非遗传因素的影响。单核苷酸多态性（SNP）rs599839和2型糖尿病（T2DM）会影响冠状动脉疾病（CAD）的发生和严重程度：我们的目的是研究 T2DM 和 rs599839 变体如何影响血清脂质水平和 CAD 患者的冠状动脉狭窄程度。入组患者被分为 A 组（360 名糖尿病患者）、B 组（225 名患有 CAD 的糖尿病患者）和 C 组（190 名健康志愿者作为对照）：结果：与 AA 基因型相比，rs599839 基因型为 GG 的糖尿病和 CAD 患者的总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）和甘油三酯（TG；分别为 224.5、116.2 和 221.4 对 251.6、131.3 和 261.7 mg/dl，P=0.003、0.007 和 0.025）均明显降低。在患有 CAD 的糖尿病患者中，rs599839 的 G 等位基因携带者的几率比和 95% 的置信区间分别为 OR = 0.62、95% CI：0.41-0.82 和 p=0.003：结论：在糖尿病并发心血管疾病患者中，1p13.3位点多态性rs599839与血清脂质水平密切相关。此外，在沙特籍糖尿病患者中，rs599839 变异的 G 等位基因可降低 CAD 风险。
{"title":"Impact of rs599839 Polymorphism on Coronary Artery Disease Risk in Saudi Diabetic Patients.","authors":"Neda M Bogari, Ahmad O Babalghith, Zohor Asaad Azher, Ahmad Hasan Mufti, Abdellatif Bouazzaoui, Hussain Banni, Abdulelah Awaji Madkhali, Ahmed Alahmadi, Reem M Allam","doi":"10.1155/2024/8278727","DOIUrl":"10.1155/2024/8278727","url":null,"abstract":"<p><strong>Background: </strong>Coronary artery diseases may be affected by several genetic and nongenetic factors. Single-nucleotide polymorphism (SNP) rs599839 and type 2 diabetes mellitus (T2DM) can affect the occurrence and severity of coronary artery disease (CAD).</p><p><strong>Methods: </strong>Our aim was to investigate how T2DM and the rs599839 variant affected serum lipid levels and the degree of CAD patients' coronary artery stenosis. rs599839 polymorphism genotyping was done on Saudi patients with coronary angiography performed previously. Patients enrolled were divided into group A (360 DM patients), group B (225 DM patients with CAD), and group C (190 healthy volunteers as control).</p><p><strong>Results: </strong>Individuals with diabetes and CAD who possessed the GG genotype in rs599839 exhibited markedly reduced means of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG; 224.5, 116.2, and 221.4 versus 251.6, 131.3, and 261.7 mg/dl, <i>p</i>=0.003, 0.007, and 0.025, respectively) than AA genotype. The odds ratio and the confidence interval of 95% for G allele carriers of rs599839 were OR = 0.62, 95% CI: 0.41-0.82, and <i>p</i>=0.003, among diabetic patients with CAD.</p><p><strong>Conclusions: </strong>In patients with diabetic CAD, the locus 1p13.3 polymorphism rs599839 was found to be substantially correlated with serum lipid levels. Furthermore, among Saudi patients with diabetes, the G allele of rs599839 variant lowers the CAD risk.</p>","PeriodicalId":11201,"journal":{"name":"Disease Markers","volume":"2024 ","pages":"8278727"},"PeriodicalIF":0.0,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11335421/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142008421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to "Fluvastatin Upregulates the α 1C Subunit of CaV1.2 Channel Expression in Vascular Smooth Muscle Cells via RhoA and ERK/p38 MAPK Pathways". 氟伐他汀通过 RhoA 和 ERK/p38 MAPK 途径上调血管平滑肌细胞中 CaV1.2 通道 α 1C 亚基的表达》的更正。
4区 医学 Q3 Medicine
Disease Markers
Pub Date : 2024-06-22 eCollection Date: 2024-01-01 DOI: 10.1155/2024/9875935
Qiu-Fang Ouyang, Ying Han, Zhi-Hong Lin, Hong Xie, Chang-Sheng Xu, Liang-Di Xie

[This corrects the article DOI: 10.1155/2014/237067.].

[This corrects the article DOI: 10.1155/2014/237067.].
{"title":"Corrigendum to \"Fluvastatin Upregulates the <i>α</i> <sub>1C</sub> Subunit of CaV1.2 Channel Expression in Vascular Smooth Muscle Cells via RhoA and ERK/p38 MAPK Pathways\".","authors":"Qiu-Fang Ouyang, Ying Han, Zhi-Hong Lin, Hong Xie, Chang-Sheng Xu, Liang-Di Xie","doi":"10.1155/2024/9875935","DOIUrl":"10.1155/2024/9875935","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1155/2014/237067.].</p>","PeriodicalId":11201,"journal":{"name":"Disease Markers","volume":"2024 ","pages":"9875935"},"PeriodicalIF":0.0,"publicationDate":"2024-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11214591/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141466857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
JAK2 as Predictor of Therapeutic Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib JAK2 作为伊马替尼治疗的慢性髓性白血病患者治疗反应的预测因子
4区 医学 Q3 Medicine
Disease Markers
Pub Date : 2024-04-12 DOI: 10.1155/2024/2906566
Indra Wijaya, Muhammad H. Bashari, Lelani Reniarti, Anita Rahmawati, Rully M. A. Roesli
Background. Chronic myeloid leukemia (CML) or chronic granulocytic leukemia is a myeloproliferative neoplasm indicated by the presence of the Philadelphia (Ph+) chromosome. First-line tyrosine kinase inhibitor, imatinib, is the gold standard for treatment. However, there has been known unresponsiveness to treatment, especially due to the involvement of other genes, such as the Janus kinase 2 (JAK2) gene. This study aimed to evaluate the relationships between JAK2 levels and complete hematological response (CHR), as well as early molecular response (EMR) after 3 months of imatinib treatment in patients with chronic phase CML. Methods. Patients with Ph+ CML in the chronic phase (n = 40; mean age, 40 ± 11 years) were recruited to complete assessments consisting of clinical examination and blood test, including evaluation of complete blood counts and the JAK2 levels, at baseline and following 3 months of therapy with imatinib (at an oral dose of 400 mg per day). Subjects were divided into two groups according to the presence of CHR and EMR. Results. JAK2 gene levels, phosphorylated, and total JAK2 proteins at baseline were significantly lower in the group with the presence of CHR and EMR. In addition, baseline JAK2 levels, including JAK2 gene expression, phosphorylated, and total JAK2 proteins, were negatively correlated with the presence of CHR and EMR. Conclusions. Based on these findings, JAK2 levels may be a potential indicator for evaluating treatment response on imatinib due to its role in the pathophysiology of CML.
背景。慢性粒细胞白血病（CML）或慢性粒细胞白血病是一种骨髓增生性肿瘤，以费城（Ph+）染色体的存在为标志。一线酪氨酸激酶抑制剂伊马替尼是治疗的金标准。然而，已知有患者对治疗不敏感，特别是由于其他基因的参与，如 Janus 激酶 2（JAK2）基因。本研究旨在评估慢性期CML患者接受伊马替尼治疗3个月后，JAK2水平与完全血液学反应（CHR）以及早期分子反应（EMR）之间的关系。研究方法招募慢性期Ph+ CML患者（n = 40；平均年龄（40 ± 11）岁），在基线和伊马替尼（口服剂量为每天400毫克）治疗3个月后，完成包括临床检查和血液检测在内的评估，其中包括全血细胞计数和JAK2水平的评估。受试者根据是否存在CHR和EMR分为两组。研究结果在存在CHR和EMR的组别中，基线时的JAK2基因水平、磷酸化和总JAK2蛋白都明显较低。此外，基线JAK2水平（包括JAK2基因表达、磷酸化和总JAK2蛋白）与是否存在CHR和EMR呈负相关。结论。基于这些发现，JAK2水平可能是评估伊马替尼治疗反应的一个潜在指标，因为它在CML的病理生理学中起着重要作用。
{"title":"JAK2 as Predictor of Therapeutic Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib","authors":"Indra Wijaya, Muhammad H. Bashari, Lelani Reniarti, Anita Rahmawati, Rully M. A. Roesli","doi":"10.1155/2024/2906566","DOIUrl":"https://doi.org/10.1155/2024/2906566","url":null,"abstract":"<i>Background</i>. Chronic myeloid leukemia (CML) or chronic granulocytic leukemia is a myeloproliferative neoplasm indicated by the presence of the Philadelphia (Ph+) chromosome. First-line tyrosine kinase inhibitor, imatinib, is the gold standard for treatment. However, there has been known unresponsiveness to treatment, especially due to the involvement of other genes, such as the Janus kinase 2 (JAK2) gene. This study aimed to evaluate the relationships between JAK2 levels and complete hematological response (CHR), as well as early molecular response (EMR) after 3 months of imatinib treatment in patients with chronic phase CML. <i>Methods</i>. Patients with Ph+ CML in the chronic phase (<i>n</i> = 40; mean age, 40 ± 11 years) were recruited to complete assessments consisting of clinical examination and blood test, including evaluation of complete blood counts and the JAK2 levels, at baseline and following 3 months of therapy with imatinib (at an oral dose of 400 mg per day). Subjects were divided into two groups according to the presence of CHR and EMR. <i>Results</i>. JAK2 gene levels, phosphorylated, and total JAK2 proteins at baseline were significantly lower in the group with the presence of CHR and EMR. In addition, baseline JAK2 levels, including JAK2 gene expression, phosphorylated, and total JAK2 proteins, were negatively correlated with the presence of CHR and EMR. <i>Conclusions</i>. Based on these findings, JAK2 levels may be a potential indicator for evaluating treatment response on imatinib due to its role in the pathophysiology of CML.","PeriodicalId":11201,"journal":{"name":"Disease Markers","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140563134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
Disease Markers
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1